Compugen Ltd. Aktie News

Compugen Ltd. (NASDAQ:CGEN ) Q1 2024 Earnings Call Transcript May 20, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of IR & Corporate Communications Anat Cohen-Dayag - President and CEO Alberto Sessa - CFO Eran Ophir - CSO Michelle Mahler - CMO Conference Call Participants Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Tony Butler - Rodman & Renshaw Operator La...

Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 + COM902 + pembrolizumab study in microsatellite stable colorectal cancer with liver metastases planned to be presented at ASCO 2024 annual meeting On track to submit IND for COM503 in the second half of 2024 with preparation for Phase 1 stud...

HOLON, Israel, May 16, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the online publication of a peer reviewed paper titled "PVRIG is expressed on stem-like T cells in dendritic cell-rich niches in tumors and its blockade may induce immune infiltration in non-inflamed ...

HOLON, Israel , May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day.

HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open.

HOLON, Israel , April 25, 2024 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of...

HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effect...

HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming investor conferences in April: 23rd Annual Needham Virtual Healthcare Conference Date: Wednesday, April 10, 2024, at 8:00 AM ET Location: V...